At a joint May 12 meeting of the Licensing Executives Society and Association of University Technology Managers, representatives of the TB Alliance and Bayer Pharmaceuticals discussed their historic moxifloxacin partnership, and the potential health benefits of similar international, collaborative efforts.
The presentation, "Perspectives and Issues in Building Global Health Alliances," outlined the Product Development Partnership (or Public-Private Partnership) model and discussed the specific terms of the TB Alliance-Bayer moxifloxacin agreement; the deal initiated a global clinical trial program – the first program to study the potential of an existing antibiotic, moxifloxacin, to significantly shorten the standard 6-month TB treatment.
The presentation was jointly given by Dick Wilder of Sidley Austin, LLC, a representative of the TB Alliance and expert on Product Development Partnerships; and Kevin Kuehm of Bayer Pharmaceuticals. Gerald J. Siuta, Ph.D, of the TB Alliance, also contributed.